PRAC considers benefits of Kogenate Bayer/Helixate NexGen outweigh risks in previously untreated patients

View source ↗

Summary

PRAC concluded that the benefits of Kogenate Bayer/Helixate NexGen outweigh the risks in previously untreated patients, informing risk-benefit considerations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Kogenate Bayer/Helixate NexGen (octocog alfa (recombinant factor VIII))